Key Points {#d30e227}
==========

Prescription of potentially inappropriate medication (PIM) leads to a significant increase in adverse drug events in the elderly.Elderly patients taking PIMs are at increased risk of PIM-related hospitalization.Other common risk factors for an increased risk of hospitalization are greater age, comorbidity and use of cardiovascular drugs.

Introduction {#Sec1}
============

Adverse drug events (ADEs) cause up to 6 % of all hospitalizations in industrialized countries \[[@CR1]--[@CR4]\]. In particular, frail elderly patients are at risk because of age-related physiological impairments, concomitant comorbidities and polypharmacy. Pharmacokinetic and pharmacodynamic alterations in the elderly may enhance sensitivity to specific drugs and make the elderly more vulnerable to ADEs \[[@CR5]\].

Evidence-based guidelines mainly address single indications only and often recommend treatment with drug combinations. Therefore, multimorbidity results in multiple drug treatment, which often generates further medication via the so-called prescribing cascade phenomenon, meaning prescription of extra medications aimed at relieving the symptoms of unrecognized ADEs \[[@CR6]\]. The lack of clinical trial data on the efficacy and safety of drugs in elderly patients contributes to this development \[[@CR7], [@CR8]\]. More than a quarter of hospital admissions in elderly patients that are due to ADEs are judged to have been preventable if more caution had been exercised in drug prescription \[[@CR4], [@CR9], [@CR10]\]. One approach to reducing ADEs in the elderly is development of explicit recommendations for drugs to be avoided. The first structured approach is the Beers Criteria, which specify "potentially inappropriate medications" (PIMs) for patients aged ≥65 years. PIMs are defined as drugs whose risks outweigh their clinical benefits, particularly when there is a safer or more effective alternative drug available for the same condition \[[@CR11]\].

To take into consideration country-specific characteristics, PIM lists have been developed in several countries (e.g. Canada \[[@CR12]\], France \[[@CR13]\], Ireland \[[@CR14]\] and Sweden \[[@CR15]\]). In Germany, the so-called PRISCUS list was published in 2010 \[[@CR16]\]. It comprises drugs that should generally be avoided and names alternatives with a better benefit-to-risk ratio in the elderly. The PRISCUS list uses the four most important international PIM lists as a reference \[[@CR12], [@CR13], [@CR17], [@CR18]\]. More than 60 % of the drugs in the PRISCUS list can be found in one of these other lists, which include a common core set of medications \[[@CR19]\]. Yet prescription of PIMs is still highly prevalent across health care systems \[[@CR11], [@CR20], [@CR21]\], with an international median prevalence rate of 20.5 % in primary care \[[@CR22]\]. For example, in Germany, one in four elderly patients receives at least one PIM as defined by the PRISCUS list (PRISCUS--PIM) \[[@CR23], [@CR24]\].

Although a significant association between prescription of PIMs and health outcomes is expected, clear evidence of causality is missing. Several systematic reviews have come to the conclusion that there is only weak evidence of an association between PIMs and adverse patient outcomes, and they have emphasized that further research is needed \[[@CR11], [@CR19], [@CR25], [@CR26]\]. The Cochrane Collaboration assessed the grade for the quality of evidence as being "very low" \[[@CR27]\], but to conduct randomized controlled trials (as the clinical gold standard), with randomization of older patients to receive a potentially high-risk drug, would be inappropriate. Therefore, other study designs are necessary.

Many earlier studies had limitations with regard to their data and methods. Important confounders such as comorbidity and temporal relationships between PIM use and outcomes were not taken into account, the samples were small, or the samples did not represent the general population.

This retrospective cohort study investigated hospitalization rates related to PIM prescription in the elderly. Additionally, other factors independently associated with hospitalization in the elderly were analysed.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

We analysed a full census of all insured patients aged ≥65 years from one of the largest public sickness funds in Germany \[Allgemeine Ortskrankenkasse (AOK) Rheinland-Hamburg\], which insures 2.8 million people. It reflects a region of Germany of about 10 million people, including rural and urban areas, of whom approximately 30 % are insured by this statutory health insurance organization. The observation period was the year 2010 to ensure we had the latest data without major changes in prescribing behaviour after the PRISCUS list was published. The data were anonymized. The following characteristics of the insured persons were available for this study: age; sex; time insured; German modification of the International Classification of Diseases 10th edition (ICD-10GM) coded diagnoses for ambulatory care, hospital stay or long-stay nursing care; and ambulatory drug prescription.

Potentially Inappropriate Medications According to the PRISCUS List {#Sec4}
-------------------------------------------------------------------

Identification of PIM prescriptions was based on the PRISCUS list \[[@CR16]\], which includes 18 therapeutic groups and 83 drugs. It specifies drugs to avoid; drugs to avoid, depending on the prescribed dose (nine drugs); and drugs with an arbitrary formulation (two drugs). For these 11 drugs, we used the central pharmaceutical number, which categorizes medications exactly into name, dose and size, to distinguish PIMs and non-PIMs. The daily defined dose was not assessed, since some medications are taken only for a limited period of time and we could not assess whether the patient took the medication, split it or took more than the normal dosage. An incident non-PIM was defined as a drug from the equivalent 18 medication groups (see Fig. [1](#Fig1){ref-type="fig"}) defined via Anatomical Therapeutic Chemical Classification System (ATC) coding (e.g. ATC codes N06A = antidepressants and N02 = analgesics). This restriction was done to exclude cases such as use of new toxic oncological drugs in the non-PIM group. Examples of non-PIMs for the indication "cardiovascular diseases" are bisoprolol or amlodipine, whereas acetyldigoxin and doxazosin are cardiovascular drugs included in the PRISCUS list.Fig. 1Patient flow: selection of the final study population. *a-/typical* typical and atypical, *PIM* potentially inappropriate medication

Study Population {#Sec5}
----------------

This retrospective cohort study was based on claims data from 647,073 insured patients aged ≥65 years.

Insured patients with PIM prescriptions were identified via the ATC. Those included in the study were all patients with at least one incident PIM prescription during the study year. Incident drug prescription was defined as prescription of a PIM during the study period AND either no PIM prescription or a non-PIM equivalent prescription within 6 months prior to the study period (the second half of 2009). Patients receiving a PIM or a non-PIM equivalent within 6 months preceding the study period or receiving simultaneous PIM and non-PIM prescriptions were excluded from the study. The time frame of 6 months was chosen to ensure that the drug was fully eliminated and to ensure reversal of any effect of tolerance. Matching variables were age, sex, drug classes, comorbidity and hospitalization in the preceding quarter, as well as insulin and phenprocoumon prescription. We included phenprocoumon (the European equivalent of warfarin) and insulin because these drugs and digoxin (a PIM) have been held responsible for many hospitalizations in previous studies \[[@CR28]\]. The maximum tolerance for matching was 0.001, based on linear predictions from a logistic regression. Figure [1](#Fig1){ref-type="fig"} describes the selection of the final study population.

Assessment of Hospitalization Risk Associated with PIM Prescribing {#Sec6}
------------------------------------------------------------------

To ensure a temporal relationship between hospital admission and PIM prescription, hospitalization within 30 days after the first prescription of a new PIM was the main outcome variable \[[@CR29], [@CR30]\]. The 30-day observation period was chosen to ensure a temporal relationship to the dispensing, as drugs often lead to adverse reactions shortly after their first application \[[@CR29], [@CR30]\]. We based the length of this time period on a set of prior studies (e.g. Singh et al. \[[@CR31]\] and Lau et al. \[[@CR32]\]) to ensure that the temporal relationship was maintained in the analyses. Choosing a shorter time period might have led to underestimation of the potential adverse effects, as some long-term effects may occur only after a longer period of time. Likewise, choice of a longer time period would have incurred a risk of overestimation of potential adverse effects, as ADEs usually occur within the first weeks of drug intake \[[@CR33], [@CR34]\]. We performed some sensitivity analyses using a 5-day period and a 90-day period. The results changed only marginally when the time lag was altered, suggesting that the method was fairly robust.

Hospital admission was counted as ADE related if the main diagnosis responsible for the admission was potentially related to ADEs, as proposed and validated by Stausberg et al. The diagnoses suggested by Stausberg have shown good results in representing plausible adverse events linked to drugs \[[@CR35]--[@CR37]\]. Under real-life conditions, detection of ADEs in elderly patients suffering from comorbidities and taking several drugs is complicated. Likewise, in our retrospective study, it was not possible to delineate a causal association between the hospitalization and the newly dispensed drug.

Statistical Analysis {#Sec7}
--------------------

Propensity score matching (PSM) was used to build a risk-adjusted control group from administrative data. PSM mimics randomization for observed variables. Propensity scores for matching are obtained through logistic regression analysis weighing covariates for the risk of hospitalization. In addition, the risk of PIM prescription and each covariate (e.g. drug classes responsible for hospital admissions due to ADEs) were estimated using logistic regression (Table [2](#Tab2){ref-type="table"}). Independent variables were age, sex, number of drugs, classes of drugs, comorbidity and hospitalization within 3 months preceding the study period, as well as insulin or phenprocoumon dispensing during the same time. The Charlson comorbidity index (CCI) was used to adjust for comorbid conditions/burden of disease \[[@CR38]\]. To verify this ICD-10 diagnoses, both outpatient and inpatient data were used for the CCI. Standard errors were computed using the robust Huber--White sandwich estimator. All analyses were performed using Stata 10.1 software.

Results {#Sec8}
=======

Final Study Population {#Sec9}
----------------------

Our final study cohort comprised 35,696 patients. PSM led to comparable study groups, each with a size of 17,848 patients. Table [1](#Tab1){ref-type="table"} shows the characteristics of the final study population. These patients received a drug from one of the 18 therapeutic groups for the first time in the observation year, 2010. About half of the study population had no comorbidity as defined by the CCI. Nearly 20 % were hospitalized within 90 days preceding the intake of any new medication, and 10 % had a diagnosis potentially caused by an adverse drug reaction, which resulted in hospitalization. Most incident prescriptions in 2010 belonged to the following therapeutic classes: analgesics (41.66 %), cardiovascular medications (36.14 %), antibiotics (17.44 %), antidepressants (5.73 %), platelet aggregation inhibitors (4.43 %) and sedatives (2.85 %).Table 1Characteristics of the final matched study population with incident PIM use and no PIM useCharacteristicNon-PIMPIMTotalPatients \[*N* (%)\]17,848 (50.00)17,848 (50.00)35,696Sex \[*N* (%)\] Female11,030 (50.56)10,785 (49.44)21,815 Male6818 (49.12)7063 (50.88)13,881Age \[*N* (%)\] 65--69 years3937 (49.80)3969 (50.20)7906 70--74 years5050 (49.75)5100 (50.25)10,150 75--79 years3857 (51.65)3611 (48.35)7468 80--84 years2752 (48.132966 (51.87)5718 85--89 years1503 (51.86)1395 (48.14)2898 90--94 years531 (48.67)560 (51.33)1091 95+ years218 (46.88)247 (53.12)465Charlson comorbidity index score \[*N* (%)\] 09675 (50.65)9428 (49.35)19,103 13580 (50.33)3533 (49.67)7113 22051 (49.53)2090 (50.47)4141 31113 (48.97)1160 (51.03)2273 4990 (47.55)1092 (52.45)2082 5+439 (44.61)545 (55.39)984Adverse drug event: hospitalization \[*N* (%)\]127 (39.44)195 (60.56)322 OR for hospitalization (95 % CI)Reference1.54 (1.23--1.93)*CI* confidence interval, *OR* odds ratio, *PIM* potentially inappropriate medication

Risk of Hospitalization {#Sec10}
-----------------------

The incidence of hospitalization differed significantly between groups, with 127 cases (39.44 %) in the control group and 195 cases (60.56 %) in the intervention group. The odds ratio (OR) for hospitalization was 1.54 \[95 % confidence interval (CI) 1.23--1.93\] for those receiving PIMs in comparison with those receiving equivalent non-PIMs.

Multivariate regression analyses assessed the influence of different covariates on hospitalization rates. Table [2](#Tab2){ref-type="table"} shows that the odds were significantly increased with PIM prescription \[OR 1.46 (95 % CI 1.16--1.84)\]. Other risks for hospitalization were greater age, higher CCI scores (with the exception of a CCI score of 5), preceding events of hospitalization \[OR 1.69 (95 % CI 1.32--2.16)\] and two drug classes: antihistamines \[OR 2.47 (95 % CI 1.30--4.71)\] and cardiovascular drugs \[OR 1.84 (95 % CI 1.40--2.41)\].Table 2Results of the logistic regression model describing the factors for each covariate associated with hospitalizationOR (95 % CI)*P* valueFirst PIM1.46 (1.16--1.84)\<0.001Age group 65--69 years1 (reference) 70--74 years1.34 (0.90--1.99)0.145 75--79 years1.83 (1.23--2.70)0.003 80--84 years2.15 (1.45--3.20)\<0.001 85--89 years2.18 (1.38--3.45)\<0.001 90--94 years2.02 (1.09--3.75)0.026 95+ years2.47 (1.08--5.65)0.032Sex Female1.00 (reference) Male0.80 (0.63--1.01)0.058Charlson Comorbidity Index score 01.00 (reference) 12.49 (1.73--3.58)\<0.001 23.32 (2.26--4.86)\<0.001 35.53 (3.74--8.20)\<0.001 49.28 (6.48--13.28)\<0.001 57.31 (4.53--11.80)\<0.001Medication Analgesics0.87 (0.66--1.16)0.345 Antidementia agents0.31 (0.08--1.29)0.108 Antidepressants1.48 (0.93--2.35)0.097 Antiemetics0.84 (0.25--2.81)0.771 Antiepileptics1.86 (0.93--3.68)0.077 Antihistamines2.47 (1.30--4.71)0.006 Antiparkinsonian agents1.68 (0.52--5.47)0.387 Antipsychotics, a-/typical1.17 (0.65--2.09)0.6 Cardiovascular drugs1.84 (1.40--2.41)\<0.001 Laxatives1.03 (0.34--3.14)0.962 Migraine agents1.40 (1.75--3.63)0.362 Muscle relaxants1.19 (0.28--5.05)0.81 Platelet aggregation inhibitors0.78 (0.49--1.23)0.285 Sedatives, hypnotics1.66 (0.94--2.92)0.078 Systemic antibiotics1.16 (0.82--1.64)0.405 Urological spasmolytics0.83 (0.26--2.67)0.753Preceding medication Insulin0.58 (0.37--0.91)0.017 Phenprocoumon2.95 (1.71--5.09)\<0.001Preceding event Hospitalization1.69 (1.32--2.16)\<0.001*a-/typical* typical and atypical, *CI* confidence interval, *OR* odds ratio, *PIM* potentially inappropriate medication

The main diagnoses responsible for hospitalization were either directly or indirectly related to the cardiovascular system, such as 'atrial fibrillation and flutter', 'atrioventricular block', 'volume depletion' or 'hypo-osmolality and hyponatraemia', which might have resulted in negative effects on the heart (Table [3](#Tab3){ref-type="table"}).Table 3Diagnoses registered at the time of hospitalizationNon-PIMPIMICD codePatients (*N*)ICD code descriptionICD codePatients (*N*)ICD code descriptionA0473Enterocolitis due to *Clostridium difficile*A0478Enterocolitis due to *Clostridium difficile*D6901Allergic purpuraE8619Volume depletionE869Volume depletionE8701Hyperosmolality and hypernatraemiaE8761HypokalaemiaE8714Hypo-osmolality and hyponatremiaF1151Mental and behavioural disorders due to use of opioidsE8751HyperkalaemiaI2606Pulmonary embolism with mention of acute cor pulmonaleH5391Visual disturbance, unspecifiedI2694Pulmonary embolism without mention of acute cor pulmonaleI2603Pulmonary embolism with mention of acute cor pulmonaleI4411Atrioventricular block, second degreeI2692Pulmonary embolism without mention of acute cor pulmonaleI4422Atrioventricular block, complete1Pulmonary embolism without mention of acute cor pulmonaleI4701Re-entry ventricular arrhythmiaI4413Atrioventricular block, second degreeI4711Supraventricular tachycardiaI4422Atrioventricular block, completeI481026Atrial fibrillation and flutterI4471Left bundle-branch block, unspecifiedI4901Ventricular fibrillation and flutterI4711Supraventricular tachycardiaI4953Sick sinus syndromeI4721Ventricular tachycardiaI4991Cardiac arrhythmia, unspecifiedI481061Atrial fibrillation and flutterI6101Intracerebral haemorrhage in hemisphere, subcorticalI4953Sick sinus syndromeI6121Intracerebral haemorrhage in hemisphere, unspecifiedI6161Intracerebral haemorrhage, multiple localizedI6131Intracerebral haemorrhage in brain stemI8001Phlebitis and thrombophlebitis of superficial vessels of lower extremitiesI6191Intracerebral haemorrhage, unspecifiedI8023Other venous embolism and thrombosisI8012Phlebitis and thrombophlebitis of femoral veinI8081Phlebitis and thrombophlebitis of other sitesI8022Other venous embolism and thrombosisI9515Orthostatic hypotensionI8031Phlebitis and thrombophlebitis of lower extremities, unspecifiedK2904Acute haemorrhagic gastritisI8081Phlebitis and thrombophlebitis of other sitesK5211Toxic gastroenteritis and colitisI9512Orthostatic hypotensionK9224Gastrointestinal haemorrhage, unspecifiedK2906Acute haemorrhagic gastritisN1784Other acute renal failureK7171Toxic liver disease with fibrosis and cirrhosis of liverN1797Acute renal failure, unspecifiedK9225Gastrointestinal haemorrhage, unspecifiedN1843Chronic kidney disease, stage 4N1782Other acute renal failureN1853Chronic kidney disease, stage 5N1797Acute renal failure, unspecifiedN1891Chronic kidney disease, unspecifiedN1831Chronic kidney disease, stage 1--5R0602DyspnoeaN1851Chronic kidney disease, stage 5R115Nausea and vomitingR0602DyspnoeaR331Retention of urineR111Nausea and vomitingR4001SomnolenceR211Rash and other nonspecific skin eruptionR423Dizziness and giddinessR331Retention of urineR512HeadacheR421Dizziness and giddinessR5521Syncope and collapseR4511Restlessness and agitationT4601Cardiac-stimulant glycosides and drugs of similar actionR511HeadacheT7831Angioneurotic oedemaR559Syncope and collapse1Syncope and collapseT4001OpioidT4241BenzodiazepinesT4641Angiotensin-converting-enzyme inhibitorsT7832Angioneurotic oedemaTotal119Total187*PIM* potentially inappropriate medication

Discussion {#Sec11}
==========

In this cohort study, we found a significant positive association between incident PIM prescription and subsequent risk of hospitalization. After mimicking randomization via PSM, patients with a PIM prescription had a 1.54-fold higher risk (95 % CI 1.23--1.93) of being hospitalized within 30 days after the first dispensing of the PIM, in comparison with the control group.

Additional multivariate regression analyses showed that other factors associated with hospitalization were age and CCI score. This finding correlates with PIM prescribing patterns, correlating positively with age, the number of comorbidities and female sex \[[@CR39]--[@CR41]\]. Incident prescriptions of two drug classes---antihistamines and cardiovascular drugs---were associated with hospitalization, whereas those for other drug classes were not statistical significant. This was probably due to the study design and the small number of remaining cases.

Other drugs that made up large proportions of the incident prescriptions, e.g. analgesics, with typical side effects on the gastrological, nephrological and cardiovascular systems, did not show statistically significant associations. However, these medications have been positively correlated with hospital admissions \[[@CR42]\]. The reason why we could not display this correlation in our study was probably due to the study design, since classical analgesic-induced ADEs, such as severe gastric ulcers, would tend to occur after our study's cut-off time of 30 days \[[@CR43]\]. This is generally the case, with some ADEs evolving at a later stage being missed. Further research analysing specific drug classes, with larger numbers of cases and designed particularly for particular drug classes and indications, is necessary for clarification \[[@CR44]\].

Results in Relation to Other Studies {#Sec12}
------------------------------------

It is difficult to compare prior studies with our study, as in many of those studies the sample sizes were small and not representative, there was no adjustment for important covariates included in the analyses, or a temporal relationship between drug use and ADEs was not taken into account \[[@CR11], [@CR19]\]. Even differences in coding and identification of ADEs need to be considered. Most mainly US studies have measured hospitalizations, either in general in the case of PIM studies, or after coding as ICD Y diagnoses in other studies. These Y codes include 'drugs, medicaments and biological substances causing adverse effects in therapeutic use' and suggest a causal relationship to ADE-related hospitalizations.

For example, Lau et al. (OR 1.27) and Dedhiya et al. (OR 1.27) also identified hospitalizations in general and reported findings similar to those in our study, though those studies had some of the previously mentioned methodological issues \[[@CR32], [@CR45]\].

Budnitz et al. analysed emergency hospitalizations caused by ADEs \[[@CR28]\] identified via ICD Y codes.

The main drugs causing ADEs in these studies were warfarin (17.3 %), insulin (13 %) and digoxin (3.2 %). Conversely, PIMs (as defined by the Beers Criteria of 2003) played only a small role (3.6 %).

It is not surprising that this kind of identification primarily captures cases that are obvious and easy to detect, such as insulin overdosing in cases of hypoglycaemia or a pathological international normalized ratio (INR) in cases of bleeding associated with warfarin. But this kind of measurement tends to underestimate many ADEs that are more ambiguous---for example, anticholinergic side effects (such as those influencing the heart rhythm or causing dizziness), for which it is harder to prove causality, especially in multimorbid patients \[[@CR46]\]. But anticholinergic and sedative medications are a major part of PIM lists and are well known to be associated with poorer performance on physical mobility and cognitive tasks \[[@CR47]\]. In a systematic review of ambulatory-based studies, for example, ADEs resulted most frequently in central nervous system (CNS) symptoms (25.1 %), followed by gastrointestinal symptoms (22.7 %) and electrolyte/renal symptoms (12.4 %) \[[@CR2]\]. Transferred to our study results, diagnoses such as 'atrial fibrillation and flutter' may be associated with side effects of a new anticholinergic PIM such as an antidepressant or neuroleptic, and alpha blockers such as doxazosin may be responsible for 'orthostatic hypotension'.

We wanted to learn from previous studies, and we refined their approaches by building comparable groups via PSM and implementing a temporal relationship to the new PIM drug intake. We detected hospitalizations in general but adapted detection to country-specific conditions by limiting our analysis to particular diagnoses that are potentially related to ADEs, as defined by Stausberg, for a retrospective study design. Our intent was to reduce bias as much as possible \[[@CR48]\].

Our results matched those of newer studies using outcome detection in general, which achieved similar results regarding PIM and hospitalization. Using the so-called Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) criteria, developed by Gallagher et al. in Ireland, Hamilton et al. found significantly higher rates of hospitalization in patients receiving PIMs (OR 1.85) and positive effects of PIM lists \[[@CR14], [@CR49], [@CR50]\].

A study design similar to ours was used by Price et al. who analysed the health profiles of 383,150 hospitalized subjects, showing that overall PIM exposure was associated with an elevated risk of hospitalization (adjusted OR 1.18) \[[@CR51]\]. This trend was confirmed in a recently published prospective study in Italian hospitals \[[@CR52]\]. A recent study in Switzerland analysed determinants of PRISCUS-PIMs and revealed that PIM use was significantly associated with hospitalization \[[@CR39]\].

Strengths and Limitations of This Study {#Sec13}
---------------------------------------

The strengths of this study were the large and representative sample and the comprehensiveness of the data. Our complex method differed from those used in other studies analysing PIMs and clinical outcomes in various respects. First, to fulfil important aspects of the Naranjo algorithm in the identification of an ADE, we focused on analysing hospitalizations and their temporal relationship to receiving a new medication \[[@CR53]\]. Second, we chose an observation time period of 30 days after intake of the new medication, since most ADEs occur soon after the initial prescribing, when the patient is not yet accustomed to the medication \[[@CR29], [@CR30]\], as in the case of falls \[[@CR33], [@CR34], [@CR54]\]. Also, by implementing a wash-out period and using PSM, we reduced selection bias and potential unintended influences of confounders.

Since previous studies found differing results, depending on whether matching was done or not, our intent was to reduce bias as much as possible \[[@CR48]\], although this resulted in a decreased study sample. Our goal was to give precision priority over quantity.

Besides its strengths, our study suffered from some of the common limitations of a retrospective design. Although control for a number of potential confounders was possible by matching, uncontrolled confounding due to missing clinical information and other unknown covariates is likely to have occurred, i.e. our analyses were not suited to studying dose dependency of subsequent ADEs, nor did we have information about the influence of over-the-counter (OTC) drugs on outcomes. Patients taking PIMs have been shown to have a slightly worse health status, which was partly accounted for by PSM and was therefore also reflected in our study population. The aforementioned advantage of analysing new use of PIMs could conversely have been a disadvantage, since some ADEs might develop only after more than 30 days, as discussed previously. Therefore, some ADEs might not have been detected. In addition, choosing to consider only individuals with a PIM-free period prior to the study may have resulted in a somehow healthier population in comparison with the average patient population. However, the CCI scores of our study population were not particularly low and could be judged to be in the average range, in comparison with the populations of other studies. Finally, given the retrospective nature of the study, one cannot conclude certainly if it was the PIM drugs per se that were dangerous for patients or if the PIM prescribing was an indicator of dangerous prescribing. We conclude that the results suggest the presence of a relationship between PIM use and specific ADEs but cannot demonstrate causality.

Value of PIM Lists {#Sec14}
------------------

PIM lists should not be seen as standalone criteria, nor do they replace individually tailored consideration of risks and benefits for the individual patient. Yet they have to be viewed in contrast to individual medication reviews, which involve a thoroughly active, time-consuming assessment of each medication, after consideration of its indication, effectiveness, dosage and other clinical information to determine its appropriateness \[[@CR55], [@CR56]\].

PIM lists are universally available, inexpensive and a time-efficient screening tool, which are an important instrument for medical reviews and can be implemented in computer software to support physicians.

This is of special interest, as the mean physician contact times with patients are only 9.0 min in Germany, 11.8 min in the UK and 20.3 min in the USA \[[@CR57]\]. Hence, hints in computer software may be valuable at the time of prescribing to prevent suboptimal drug choices---for example, through prior physician education \[[@CR40]\]. Mattison et al. reported a decrease in PIM prescribing after implementation of an effectively computerized provider order entry warning system \[[@CR58]\].

Conclusion {#Sec15}
==========

Use of PIMs in the elderly is a major public health concern. These explicit (criterion-based) PIM lists should not be seen as standalone criteria, nor do they replace individually tailored consideration of risks and benefits for the individual patient.

Implicit (judgment-based) criteria might perform better concerning clinical outcomes. However, implicit criteria also require considerable time for assessment of each medication, after consideration of its indication, effectiveness, dosage and other clinical information to determine its appropriateness \[[@CR55], [@CR56]\]. Instead, PIM lists are universally available, inexpensive and a time-efficient screening tool, which are an important instrument for medical reviews and can be implemented in computer software to support physicians.

Our study suggests that elderly patients taking PRISCUS-PIMs are more likely to suffer from ADEs, leading to an increased risk of hospitalization. This study supports the increasing consensus to avoid new prescribing of PIMs \[[@CR11], [@CR56], [@CR59]\].
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